CDC’s Vaccines for Children Program Addendum : Special Considerations for Nirsevimab

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.)
• Description:
  Nirsevimab is an FDA-licensed monoclonal antibody that provides passive immunity against RSV-associated infection. On August 3, 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend nirsevimab as an immunization for all infants aged <8 months, as well as some children up to age 20 months (see ACIP recommendations), and a VFC resolution was passed to include nirsevimab in the VFC program. This addendum provides supplemental information and guidance related to the addition of the nirsevimab immunization to the VFC formulary.
  
  NCIRDwt
  
  operations-guide-nirsevimab-addendum.pdf
  
  
• Subjects:
  Infant, Newborn Pregnancy Pregnant Women Respiratory Syncytial Virus Infections/prevention & Control
• Series:
  Vaccines for Children
• Document Type:
  Text
• Name as Subject:
  Nirsevimab ; Nirsevimab
• Genre:
  Fact Sheet
• Place as Subject:
  United States
• Pages in Document:
  2 unnumbered pages
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha-512:4ff95ceb9233442704c70630b9e14fd8a616eb27d60d2afff87b1b88bac6c3d32ab11d5601f57d6956a435029f5a6c090a7700dc58f457846d3b34a5b838902c
• Download URL:
  https://stacks.cdc.gov/view/cdc/134195/cdc_134195_DS1.pdf
• File Type:
  [PDF - 156.47 KB ]